眼内恶性肿瘤生物治疗的研究进展  

Advances of Biotherapy for Treating Intraocular Malignant Tumor

作　　者：李雨心 魏炜[2] 陶勇[1] 王晓君 Yuxin Li;Wei Wei;Yong Tao;Xiaojun Wang(Department of Ophthalmology,Beijing Chaoyang Hospital,Capital Medical University,Beijing 100020,China;State Key Laboratory of Biochemical Engineering,Institute of Process Engineering,Chinese Academy of Sciences,Beijing 100190,China)

机构地区：[1]首都医科大学附属北京朝阳医院眼科,北京100020 [2]中国科学院过程工程研究所生化工程国家重点实验室,北京100190

出　　处：《中华眼视光学与视觉科学杂志》2023年第7期544-549,共6页Chinese Journal Of Optometry Ophthalmology And Visual Science

基　　金：国家自然科学基金面上基金(82070948);北京市医院管理中心登峰计划(DFL20220301);北京朝阳医院金种子科研基金(CYJZ202139)。

摘　　要：眼内恶性肿瘤多发于视网膜和葡萄膜,是严重的致盲性疾病,甚至可危及患者的生命。随着生物技术的迅速发展,眼内恶性肿瘤生物治疗主要包括免疫治疗、小分子靶向治疗、基因治疗和溶瘤病毒治疗等。笔者将重点关注儿童及成人患病率最高的眼内恶性肿瘤(即视网膜母细胞瘤和葡萄膜黑色素瘤),对生物治疗在其基础和临床研究中的最新进展进行综述,并对生物治疗存在的挑战和未来发展方向进行展望。Intraocular malignant tumors,which are serious blinding diseases and can even be life-threatening,mostly occur in the retina and uvea.With the rapid development of biotechnology,biotherapy for intraocular malignant tumors has evolved to include immunotherapy,small molecule targeted therapy,gene therapy and oncolytic virus therapy.This review summarized the recent advances,current problems,and future perspectives in the fundamental and clinical research of biotherapy for treating retinoblastoma and uveal melanoma,the most common primary intraocular malignancies in children and adults.

关 键 词：生物治疗 眼内恶性肿瘤 免疫治疗 小分子抑制剂 基因治疗 溶瘤病毒 

分 类 号：R739.7[医药卫生—肿瘤]